Pfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favorable European court ruling on its COVID-19 vaccine would help secure stronger growth after 2028.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets